Interferon alfa-2a / alfa-2b
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-INTERFERON-ALPHA |
|---|---|
| Type | Drug |
| Aliases | Interferon alfaIntron ARoferon-AІнтерферон альфа |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ATLL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Type-I interferon (immunomodulator) |
|---|---|
| Mechanism | Binds type-I interferon receptor (IFNAR), inducing JAK-STAT signaling → upregulation of MHC-I, NK-cell activity, Th1 polarization, direct antiproliferative effect. In ATLL, synergizes with zidovudine (AZT/IFN-α) by inducing apoptosis of HTLV-1-infected cells. |
| Typical dosing | ATLL (AZT/IFN-α): IFN-α 5-9 million IU/day SC continuous indefinitely (with AZT 600-1000 mg/day). Dose-adjusted for cytopenias and depression. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Neuropsychiatric (depression, suicidality)
- Autoimmune disorders (thyroid, hepatitis, lupus-like)
- Ischemic events (cardiac, cerebrovascular)
- Infectious complications
Notes
ATLL indolent (chronic / smoldering) responds to AZT/IFN-α with ORR ~80% (Bazarbachi 2010 meta-analysis) and substantial OS benefit vs chemotherapy in this subtype — class-defining therapy. Aggressive ATLL (acute / lymphomatous) — chemotherapy first (CHOEP / VCAP-AMP-VECP) followed by alloHCT consolidation preferred over AZT/IFN-α. In MPN (PV/ET high-risk requiring cytoreduction): IFN-α (or pegylated IFN-α-2a or ropeginterferon alfa-2b) is an alternative to hydroxyurea, particularly favored in younger patients, those of childbearing potential, and post- HU intolerance. CML — superseded by TKIs since 2001 (IRIS). Mandatory baseline psychiatric assessment (PHQ-9 / GAD-7); TSH + liver enzymes q3 months; CBC monthly. Dose-reduce for ANC <1.0, plt <50, depression PHQ-9 ≥10, severe flu-like symptoms. UA: доступний як Roferon-A / Intron A; НСЗУ покриває в окремих показаннях (передусім МПН).
Used By
Contraindications
CI-PSYCH-DECOMPENSATED-FOR-INTERFERON- CI-PSYCH-DECOMPENSATED-FOR-INTERFERON
Regimens
REG-AZT-IFN-A- AZT (zidovudine) + IFN-α — continuous, dose-adjusted
Supportive Care
SUP-PSYCH-MONITORING-IFN- Neuropsychiatric monitoring during interferon-α therapy